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BACKGROUND: Cyclophosphamide (CPA) is an anti- cancer 
drug, used in chemotherapy. This is a toxic drug which targets the 
cancer cells and also the normal cells of the body. The original 
compound is inactive in vitro and exercises its biologic action 
through metabolites, chiefly phosphoramide mustard. The 
objective is to study the harmful effects of this drug on liver and 
kidney tissues. 
METHODS: To study the effect of cyclophosphamide on histology 
of liver and kidney, 40 adult male mice were taken and divided into 
two groups: control and test. Those in the test group were injected 
with the drug at doses of 100, 200, 250 mg/kg body weight. They 
were then sacrificed on day 7, 28 and 42. The liver and kidney 
tissue was processed, sectioned and stained with Haematoxylin 
and Eosin.  
RESULTS: Pathological changes were seen in the tissue within 7 
days in high doses and after 28 days in low doses.  As the dosage 
and the days administered increased, the changes were 
prominently seen and widespread. Pathology ranging from mild 
infiltration to necrosis and finally cytolysis were seen in liver and 
kidney tissue.  
CONCLUSION: Our study has demonstrated the effect of a 
progressive increase in dosage of cyclophosphamide in albino 
mice, and pathological alterations were observed in histology of 
liver and kidney by sequentially increasing both the dosage and 
duration of treatment.  Subsequently, regular monitoring of liver 
and kidney function tests in patients undergoing chemotherapeutic 
regimen with administration of ahepato and nephroprotective 
agent becomes vital. 
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Cyclophosphamide (CPA) is an oxazaphosphorine class of 
alkylating agent. An alkylating agent is a class of drugs that bind to 
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anucleophilic substance of 
DNA of the cell and prevent 
its replication. It is administered orally or intravenously (1). The 
original compound is inactive in vitro and exercises 
its biologic action through metabolites, chiefly 
phosphoramide mustardwhich is produced by 
hepatic microsomal enzymes P450 system. However 
more than 150 metabolites have been documented 
so far, but their pharmacokinetics and harmfulness 
are not well demarcated (2).The main use of CPA is 
as a chemotherapy drug permitted for usage in the 
United States in 1959, and its existing indications 
include management of breast cancer, non-
Hodgkin's lymphoma, acute myeloid leukemia, 
chronic myelogenous leukemia and acute 
lymphoblastic leukemia (3). CPA treatment for 3 
days showed bone marrow suppression, significantly 
decreasing hemoglobin, RBC, and WBC levels. It 
also acts on the defense mechanism inhibiting both 
cell-mediated and humoral immunity (4). 
As it also exhibits immunosuppressive actions, 
it is frequently used in autoimmune disorders such 
as Nephrotic syndrome, and organ transplant 
treatment regimens to prevent rejection. CPA 
prevents cellular/ humoral rejection and maintains 
immunosuppression without requiring the 
supplementation of corticosteroids (5).The 
recommended dosage of CPA for treatment differs 
with the duration of the disease, the weight of the 
patient and the route of administration (6). 
Although it is very active in killing tumor cells 
and plays a key role in immunosuppression, it also 
displays a wide range of toxic effects. Oral 
administration of 10mg/kg of CPA for 30 days 
induced decrease in body weight and delayed 
hypersensitivity reaction in Wisteria rats. The 
histopathology of spleen and thymus showed 
asignificant decrease in cellularity. The CPA-
induced liver injury is mainly dose-dependent. 
Apparently, it is a consequence of compromised 
metabolism of CPA, particularly of its metabolite, 
acrolein (6). 
Increased exposure to metabolites of CPA 
leads to hepatotoxicity, symptoms of liver 
dysfunction related to sinusoidal obstruction 
syndrome with raised level of aminotransferase and 
bilirubin (7). In themajority of cases with cancer, 
which were treated with cyclophosphamide, slight 
and transient elevations in serum aminotransferase 
levels were observed.The rise in the level of 
enzymes is more seen in cases treated with high 
doses of CPA administered directly into the blood 
through intravenous route (8). 
Regular doses of cyclophosphamide producing 
clinically apparent liver and kidney injuries are 
unusual.  The commencement is within the first few 
weeks of CPA therapy, and initially increase in 
serum enzymes is observed. The destruction in most 
cases is self-limited, and resolutions areapparent on 
discontinuing the drug with a recurrence on re-
exposure (9). 
In the literature, several experimental animal 
studies with CPA have been done. It shows the 
adverse effects of CPA on the tissues. A study on 
histopathology of the liver of Swiss albino mice 
shows signs of hepatic degeneration (10-11). 
Previous studies focussed mainly on a few optimal 
concentration that could be toxic to the cells. 
However, in the present study different doses in 
increasing order were administered to the animals. 
Additionally,tissues were procured at regular 
intervals, unlike former studies which processed 
tissues at the end of the treatment plan. The aim of 
this study was to examine the histology of liver and 
kidney of Swiss albino mice acquired at regular 
intervals after treatment with CPA in increasing 
doses. 
 
MATERIALS AND METHODS 
 
Animal model: Healthy male Swiss albino (Mus 
musculus) mice from inbred colony maintained at 
Central Animal Research Facility (Reg No 
94/1999/CPCSEA) were used for the study.  Forty 
adult mice with average weight of 32±5 g were 
maintained in well ventilated polypropylene cages 
containing paddy husk. Animals were given food 
and fresh water ad libitum. The protocol for animal 
use was approved from the Institutional Animal 
Ethics Committee (IAEC Ref No-79/2013). 
Experimental design: The adult male mice were 
divided into two groups; control (n=6) and test 
(n=34). Since the daily oral therapeutic dose of 
cyclophosphamide for human beings is 5mg/kg 
body weight so from this dose the dose for albino 
rats was calculated (3,12). In the test group, the mice 
were intra-peritoneally injected with CPA single 
dose of 100, 200 and 250mg/kg body weight.  From 
each group, 4 mice were sacrificed on days 7, 28 
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and 42. The control mice were injected with 
Phosphate Buffered Saline (PBS) solution.  
Collection of liver and kidney: On the specific 
period, animals were sacrificed by cervical 
dislocation. The mice were dissected as per 
guidelines given in “The Laboratory Mouse-
Handbook of experimental animals” by Hans 
Hedrich. A midline incision was given on the 
abdomen with the help of scalpel, the organs liver 
and kidney were identified and dissected out. The 
tissues were fixed in modified Bouin’s solution 
(0.2% picric acid 2% (v/v) formaldehyde in PBS) 
and then transferred to 70% alcohol for histological 
examination.  
Histological technique: The tissues stored were 
processed by dehydration in 90% alcohol, absolute 
alcohol and finally dipped in xylol. The organs 
(liver and kidney) were embedded in paraffin wax 
and blocks were prepared and labelled. 5µm 
thickness sections were cut using rotatory 
microtome. The sections were fixed on slides and 
stained using Haematoxylin and Eosin according to 
the guidelines given in the manual Principles and 
Techniques in Histology Microscopy and 
Photomicrography by D. R. Singh (13). 
Histological assessment: Stained sections were 
studied under Olympus Research Microscope 
(model cx21i) and photographed at 10X and 100X 
magnification in at least three random microscopic 
fields from each animal by expert pathologist 
without knowledge of the treatment groups. Three 
factors such as hepatocellular necrosis, level of 
inflammatory in-portal area, and lymphocytic 
inflammatory infiltrations were evaluated using 
semiquantitative method. Similarly, from kidney 
sections, the structures of cortex, medulla and 




Control group: Histological examination of liver 
tissue in this group displayed normal microstructure. 
Distinct hepatic lobules were seen, cords of 
hepatocytes were separated with sinusoids. Central 
vein and portal triad were also perceived to be 
normal (Figure 1.1). 
100mg CPA-treated group: At 7 days, mild 
histological changes were seen in this group. In 
animals sacrificed at 7days, the changes in liver seen 
were mild peri-venular infiltration. The hepatocytes 
and sinusoids appeared normal (Figure 1.2).  In 
kidney sections, some areas of cortex showed 
infiltrate. There was rarefaction of cytoplasm of the 
tubules in the junction of cortex and medulla. 
(Figure 4.2). 
At 28 days: The central vein and portal veins of 
liver were engorged. The hepatocytes still appeared 
normal. Multinucleated megakaryocytes were seen 
in the hepatic lobules (Figure 1.3).   
Kidney: Inflammatory cells seen are same as 
previous sections. Outer most cortex shows swelling 
of cells and rarefaction of cytoplasm which was 
present in the junction in the previous sections. 
Medulla also shows swollen cells (Figure 4.3).   
At 42 days: Slight enlargement of hepatocytes in 
liver were seen; there was increased infiltration of 
inflammatory cells into the liver tissue. There is 
both central and portal venous engorgement (Figure 
1.4)   
Kidney: A large number of pyknotic nucleus was 
seen in the cortex. Inflammatory cells increased in 
the outer cortex. (Figure 4.4) 
200mg CPA-treated group: In this group, the 
changes were seen earlier than the previous group.  
At 7 days on liver: The hepatocytes and sinusoids 
showed no change from the control group. 
Megakaryocytes were seen in between the tissue 
(Figure 2.2).   
Kidney: Inflammatory cells reduced. Oedematous 
changes of the tubules in cortex is more striking. 
Cortex shows sloughing off cells. Pyknotic nucleus 
present in thecortex. Medulla shows only swelling 
of cells and no other major changes (Figure 5.2).   
At 28 days: Hepatocytes were swollen, sinusoids 
were congested. Portal and central vein were normal 
and the infiltrate absent. (Figure 2.3).   
Kidney: Pyknotic nucleus seen in cortex, loss of 
brush border of the tubules. Congestion of the 
vessels is reduced. Inflammatory cells reduced. 
Medulla shows swollen cells. (Figure 5.3).   
At 42 days: The hepatocytes were enlarged- 
ballooning effect. Sinusoids were markedly 
congested and periductular necrosis is present. 
(Figure 2.4).   
Kidney: Swollen cells of PCT with theoccasional 
absence of anucleus. Inflammatory cells increased. 
Congestion of blood vessels is minimal. Medulla 
shows large cells. (Figure 5.4).   
250 mg CPA-treated group:  As this is ahigh dose, 
the toxic effects were markedly seen on the 
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microstructure of liver tissue. The changes were 
more pronounced.  
At 7 days: The hepatocytes were swollen, sinusoids 
were enlarged, perivenular spotty necrosis and 
venous engorgement was seen (Figure 3.2).   
Kidney: No inflammatory cells seen. Increased 
number of pyknoticnuclei. Blood vessels show 
marked congestion. Medulla shows increase in 
swelling of cells. (Figure 6.2).   
At 28 days on liver: The normal structure of 
hepatic lobule was lost. There was cytolysis that is 
the cell membrane wasdamaged;Nucleuswas present 
whichwas small and pyknotic. There was minimal 
infiltration but marked dilatation of veins (Figure 
3.3).   
Kidney: congestion of blood vessels present. No 
presence of inflammatory cells. Normal nucleus. 
Swelling of cells all throughout medulla and cortex. 
(Figure 6.3).   
At 42 days on liver: Cytolysis with pyknotic 
nucleus was seen. Spotty necrosis and marked 
venous engorgement of veins. Normal architecture 
of liver tissue was damaged. The cords of 
hepatocytes were no longer seen. The sinusoids 
were disrupted, the veins were significantly dilated 
occupying large areas. (Figure 3.4).   
Kidney: Appearance of pyknotic nucleus, oedema 
of cells and loss of brush border same as thelast 
section.  (Figure 6.4).  
 
 
Figure 1: Haematoxylin and Eosin stained liver tissue , 40X, 100mg CPA treated group. 1.1: Control, Liver tissue shows normal 
hepatocytes and sinusoids. 1.2: At 7 days: Multinucleated megakaryocytes are seen.  1.3: At 28 days, The portal vein is engorged. 





Figure 2: Haematoxylin and Eosin stained liver tissue, 40X, 200mg CPA treated group. 2.1: Control, The hepatocytes and 
sinusoids are normal.  2.2: At 7 days, The hepatocytes and sinusoids are normal. Megakaryocytes are seen in lobules.  2.3: At 28 
days, Hepatocytes are swollen, sinusoids are congested.  2.4: At 42 days, The hepatocytes are enlarged- ballooning effect. 
Enlarged portal vein and periductular necrosis is present 
 
 
Figure 3: Haematoxylin and Eosin stained liver tissue, 40X, 250mg CPA treated group. 3.1: Control, The hepatocytes, sinusoids 
and veins normal.  3.2: At 7 days, The hepatocytes are swollen, sinusoids are enlarged.  3.3: At 28 days, The normal structure of 
hepatic lobule is lost. There is cytolysis that is the cell membrane is damaged, Nucleus is present which is small and pykonotic. 
There is minimal infiltration.  3.4: At 42 days, Cytolysis with pykonotic nucleus is seen. Spotty necrosis and marked venous 
engorgement of veins. Normal architecture of liver tissue is damaged. The cords of hepatocytes are no longer seen. The sinusoids 
are disrupted and are significantly dilated occupying large areas.  
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Figure 4: Haematoxylin and Eosin stained kidney tissue, 40X, 100mg CPA treated group. 4.1: Control, Kidney 
cortex and medulla shows normal architecture 4.2: At 7 days, rarefaction of cytoplasm of the tubules in the cortex.  




Figure 5: Haematoxylin and Eosin stained kidney tissue, 40X, 200mg CPA treated group 5.1: Control, Kidney 
section showing normal structure. 5.2: At 7days, Pyknotic nuclei increased. 5.3: At 28 days, swollen cells occasional 
nucleus absent. 5.4: At 42 days, No inflammatory cells, pykontic nucleus. 
 
 
Figure 6: Haematoxylin and Eosin stained kidney tissue, 10X, 250mg CPA treated group 6.1: Control, Kidney 
section showing normal structure under higher magnification;  6.2: At 7 days, Congestion, swelling of tubules, loss of 
brush border; Fig 6.3: At 28 days, Marked congestion;  6.4: At 42 days, Necrotic tissue seen 
 
DISCUSSION  
Cancer in the human body is treated with numerous 
diverse chemotherapeutic agents. The therapeutic 
drugs can be categorized into different types. Some 
modules of chemotherapy act by generating oxidative 
stress or free radicals.They are recognizedvto halt 
cancer development through cross-linking nucleobases 
in DNA, consequently harming the DNA, rendering it 
incapable of uncoiling. The cell is then unable to 
replicate (7). CPA belongs to this cytotoxic alkylating 
group of drugs. It is bio-activated by hepatic 
cytochrome P450 enzymes ensuing in the productionof 
its two metabolites: phosphoramidemustard and 
acrolein. Acrolein, a  byproductmetabolite of CPA, 
obstructs the tissue antioxidant defense system, 
producesreactive oxygen species (ROS), and interacts 
with protein amino acids causing structural and 
functional changes (12). 
In a study conducted by Kah et.al on adult wistar rats 
treated with CPA, the liver tissue showed fatty 
infilteration with normal central vein and portal triad in 
low doses (3). In this study, venous congestion and 
mononuclear cell infilteration was seen in periportal 
area in low doses, but there was no fatty degeneration 
observed. This difference in studies  may be due to the 
variance in mode of administration which is intra 
peritoneal injection in the present study whereas  oral 
routeadministration was done in the previous study. In 
this study, we observed CPA-induced necrotic changes 
in dose and duration dependent manner. The changes 
observed were cellular disintegration, distortion and 
pyknotic nuclei with congestion of blood vessels and 
leucocyte migrations. The histological comment in the 
current study was similar to studies conducted by 
various authors in the past (3,10,11,12). In in-vitro, the 
endothelial cells lining the sinusoids of the liver are 
injured by the metabolites of CPA causing veno 
occlusive disease also known as sinusoidal obstruction 
syndrome (10). The histological findings in this study 
such as portal vein engorgement, sinusoidal congestion 
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and subsequently hepatocyte degeneration suggest 
veno occlusive disease consequent to increase in 
oxidative stress. 
According to researchers, CPA does not show 
any adverse effect on the kidney. This is because, its 
by-product, acrolein is not nephrotoxic and is more of 
urotoxic (14). However, in our study, we have seen 
pathological changes such as infilteration ofacute 
inflammatory cells in the cortex, oedema of tubular 
cells, loss of brush border and finally pyknotic  cells. 
Similar changes were also suggested by Sakr et.al.who 
injected CPA  and observed dilation and congestion of 
renal blood vessel, vacuolations of epithelial lining 
renal tubules and atrophy of glomerular tuft. The 
changes were credited to CP-induced oxidative stress 
as perceived by the escalation in the oxidative markers 
in the kidney tissues (15). 
The histological changes therefore seen in the 
liver and kidney tissues in this study may also be 
attributed to the increase in the oxidative stress of the 
cell and decrease in the antioxidant agents. Hence, 
there is the importance of hepatoprotective and 
renoprotective drug administration, preferably an 
antioxidant before using chemotherapeutic agents in 
patients with malignancies and also regular monitoring 
of liver and kidney function tests in patients 
undergoing chemotherapeutic regimen.  
Our study has demonstrated the effect of 
aprogressive increase in dosage of CPA in Swiss 
albino mice and pathological alterations observed in 
histology of liver and kidney by sequentially 
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